Introduction
============

Alzheimer\'s disease (AD) is a neurodegenerative disorder with progressive cognitive impairment. Molecular genetic studies have demonstrated the presence of complex genetic heterogeneity in AD ([@b1-etm-0-0-3734]--[@b3-etm-0-0-3734]). Previous investigations reported that certain gene mutations are associated with familial early-onset AD, such as amyloid-β precursor protein, presenilin I and presenilin II ([@b3-etm-0-0-3734]--[@b5-etm-0-0-3734]). In addition, it was demonstrated that there are likely numerous gene polymorphisms that are risk factors for late-onset AD (LOAD), but to date, only the apolipoprotein E (APOE) ε4 allele has been widely confirmed as a susceptibility gene for LOAD ([@b1-etm-0-0-3734]). However, the APOE gene polymorphism may only contribute to 50% of genetic susceptibility ([@b1-etm-0-0-3734]). This suggests there may be other genes that could influence susceptibility to the onset of LOAD. The investigation of other susceptibility genes would facilitate the research on LOAD pathogenesis.

In 1996, the clusterin (*CLU*) gene was suggested to be a potential AD susceptibility gene ([@b2-etm-0-0-3734]). The *CLU* gene is located at p21-p12 of chromosome 8 ([@b5-etm-0-0-3734]). The protein expressed by *CLU* is known as apolipoprotein J which is secreted by neurons and astrocytes, and being the second-largest glycoprotein in the brain following APOE, it has similar biological functions to APOE ([@b5-etm-0-0-3734]). *CLU* is expressed in cerebrospinal fluid and amyloid plaques in brain tissues, is able to combine with β-amyloid peptide to participate in the processes of metabolism, transportation and clearance of amyloid-β (Aβ), and has an important role in the cell cycle regulation and lipid metabolism of AD ([@b3-etm-0-0-3734]--[@b5-etm-0-0-3734]). A previous study reported that the *CLU* gene may be associated with AD ([@b2-etm-0-0-3734]). Unfortunately, no gene locus identified in the earliest study regarding the correlation between *CLU* gene variants and AD ([@b2-etm-0-0-3734]).

With the advance of molecular genetic technology, it became possible to include significantly greater numbers of individuals in the disease-association studies, thereby allowing the identification of more potential disease susceptibility genes. In October 2009, 'Nature Genetics' simultaneously published two AD-associated large-scale genome-wide association studies (GWAS) completed by Lambert *et al* ([@b6-etm-0-0-3734]) and Harold *et al* ([@b7-etm-0-0-3734]), which both confirmed that the *CLU* gene single nucleotide polymorphism (SNP) rs11136000 was associated with LOAD. Another meta-analysis of genome-wide detection also suggested that the p22-p21.1 of chromosome 8, namely the *CLU* chromosomal locus, was a LOAD-associated susceptibility region ([@b8-etm-0-0-3734]). Since then, the association between AD and *CLU* variants has once again become the focus of numerous studies, in which various experiments were carried out in an attempt to demonstrated the correlation ([@b9-etm-0-0-3734]--[@b26-etm-0-0-3734]). However, the results of these studies were not concordant.

The present investigation reviewed and conducted a meta-analysis of previously published case-control studies on the correlation between the *CLU* gene polymorphism rs11136000 and LOAD both in China and abroad. The increased sample size could improve the significance of the results, and subgroup analyses of various ethnicities could eliminate possible ethnic differences. The aim of the present study was to provide objective evidence-based results for the association between *CLU* gene polymorphisms and AD susceptibility.

Materials and methods
=====================

### Subjects

The previously published case-control studies regarding the association between *CLU* gene variants and LOAD in various ethnic groups were reviewed. The patients with LOAD in these studies were selected as study cases, and the *CLU* rs11136000 polymorphism as the locus of interest, which in the previous studies was demonstrated to be significant although controversial. The control groups in these studies were healthy participants of the same ethnicity as the cases studied. The genotype frequencies of TT, TC and CC, as well as the allele frequencies of T and C, in the case and control groups of these studies were obtained for meta-analysis. The control groups in this study were healthy participants with the same ethnicity as the cases studied.

### Literature search

A systematic search was conducted using PubMed ([www.ncbi.nlm.nih.gov/pubmed](www.ncbi.nlm.nih.gov/pubmed)), EMbase ([store.elsevier.com/embase](store.elsevier.com/embase)), CBMdisc ([www.cnki.com.cn](www.cnki.com.cn)), CMCC, Wanfang ([www.wanfangdata.com.cn](www.wanfangdata.com.cn)), and other databases in English or Chinese (the last search was updated on August 31, 2014), with 'Clusterin AND Alzheimer disease' as MeSH terms, and 'Clusterin AND Alzheimer' and 'rs11136000' as free terms. Through literature retrospection, the references of the retrieved studies were further reviewed to ensure that a comprehensive selection of the relevant studies was carried out. According to the abstracts provided by the databases, the original sources of the studies were located in order to obtain full texts and complete data.

### Inclusion criteria and quality control

All the participanting authors evaluated the quality of the selected studies and reached a consensus regarding the appropriate inclusion criteria and quality control. Studies meeting the following criteria were included in the meta-analysis: 1) Case-control studies involving the polymorphism rs11136000; 2) LOAD cases diagnosed according to the internationally accepted standards, DSM-IV and NINCDS-ADRDA ([@b27-etm-0-0-3734]), with the controls being local matched healthy individuals; 3) sample size was explicit, genotype and allele frequency data could be obtained, original data was provided directly or could be used to calculate the odds ratio (OR) and 95% confidence intervals (CI), and information was sufficient to compare the statistical differences between the groups; 4) experimental methods for detecting gene polymorphisms were scientific and rigorous; and 5) allele frequency met the Hardy-Weinberg equilibrium (HWE). The articles published with incomplete data were excluded from the meta-analysis. Among repeatedly reported studies, those with the most complete information were used.

### Statistical analysis

RevMan5.2 version 5.2 (The Nordic Cochrane Centre, The Cochrane Collaboration, Oxford, UK) and Stata 11.0 software version 11.0 (StataCorp LP, College Station, TX, USA) were used for statistical analysis.

### HWE test

A χ^2^ test was used to investigate the HWE of rs11136000 allele distributions among the selected studies, in order to verify the representativeness of the study population. Studies in which the allele frequency of the control group did not satisfy HWE law were removed.

### Heterogeneity test

A *Q* test was performed to examine the heterogeneity among the selected studies. RevMan software provided the P-value of the *Q* tests, with P\<0.10 considered to indicate a statistically significant difference. Different effect models for meta-analysis were selected based on the results of the *Q* tests.

### Selection of statistical models

If there was no statistically significant heterogeneity among the results of the studies, a Peto Mantel-Haenszel fixed-effect model was used to determine the overall OR. If there was statistically significant heterogeneity, a Dersimonian-Laird random-effect model was used. The RevMan software provided the overall OR and its 95% CI.

### Test for overall effect

Forest plots were provided by the RevMan software, on which the *Z* and P-values were shown on the 'test for overall effect', with P\<0.05 considered to indicate a statistically significant difference.

### Bias analysis

Funnel plots were generated by the RevMan software for the preliminary analysis of publication bias. Using the Stata software, Egger\'s linear regression and Begg\'s rank correlation tests were performed to objectively evaluate publication bias and to verify the symmetry of the funnel plots, with P\<0.10 considered to indicate a statistically significant difference. Lastly, the fail-safe number (N~fs~) was calculated to further measure publication bias using the following formula: N~fs0.05~ = (ΣZ/1.64)^2^ - k. The larger the N~fs~ value, the smaller the bias.

Results
=======

### Characteristics of eligible studies

Following a literature review and further screening according to the inclusion criteria, 20 studies were included in the meta-analysis ([Fig. 1](#f1-etm-0-0-3734){ref-type="fig"}) ([@b6-etm-0-0-3734],[@b7-etm-0-0-3734],[@b9-etm-0-0-3734]--[@b26-etm-0-0-3734]), all of which were published after 2009 in foreign biomedical journals, but not reported in Chinese journals. The study population of these investigations included Caucasian, Hispanic, and Asian populations, populations of African descent, as well as other ethnicities, of which 12 were from Europe or America, and 8 were from Asia. A total of 32,017 individuals with LOAD were included as cases, whose diagnoses were predominantly based on the clinical criteria, with only a minority diagnosed based on pathological evidence. A total of 43,956 individuals were included as controls, in which the allele distributions were in accordance with the HWE. The characteristics of the eligible studies are shown in [Table I](#tI-etm-0-0-3734){ref-type="table"}. The genotype and allele frequencies of the *CLU* gene polymorphism rs11136000 are shown in [Table II](#tII-etm-0-0-3734){ref-type="table"}.

### Considering ethnic differences, subgroup meta-analyses were conducted according to five ethnicities (Caucasian, Asian, African descent, Hispanic and other/mixed ethnicities)

Using the (TT+TC)/CC genotype model ([Fig. 2](#f2-etm-0-0-3734){ref-type="fig"}), a significant heterogeneity was observed in the Caucasian population with P=0.0004, although no significant heterogeneity was observed in the Asian population with P=0.38. Using the T/C allele model ([Fig. 3](#f3-etm-0-0-3734){ref-type="fig"}), statistically significant heterogeneity was not observed in the Caucasian population with P=0.57, nor in the Asian (P=0.47) or other/mixed ethnicity populations (P=0.27). No heterogeneity tests were required in the ethnic subgroups in which only one study was eligible.

### Meta-analysis

The random-effect model was used to test for the overall effect of the (TT+TC)/CC genotype model in the Caucasian population ([Fig. 2A](#f2-etm-0-0-3734){ref-type="fig"}), in which a statistically significant difference was observed (overall OR, 0.79; 95% CI, 0.73--0.86; P\<0.00001). The fixed-effect model was used in the Asian population for the (TT+TC)/CC genotype model ([Fig. 2B](#f2-etm-0-0-3734){ref-type="fig"}), and a statistically significant difference was also observed (overall OR, 0.90; 95% CI, 0.81--0.99; P=0.04). The fixed-effect model was used in the Caucasian, Asian and other/mixed ethnicity populations for the T/C allele model ([Fig. 3](#f3-etm-0-0-3734){ref-type="fig"}), and statistically significant differences were observed for all ethnicities (Caucasian: Overall OR, 0.87; 95% CI, 0.85--0.90; P\<0.00001; Asian: Overall OR, 0.87; 95% CI, 0.81--0.93; P\<0.0001; other/mixed ethnicities: Overall OR, 0.82; 95% CI, 0.68--0.99; P=0.04). Statistically significant differences were not however observed in the populations of African descent (overall OR, 1.06; 95% CI, 0.88--1.28; P=0.54) or Hispanics (overall OR, 1.10; 95% CI, 0.93--1.30; P=0.27) for the T/C allele model ([Fig. 3](#f3-etm-0-0-3734){ref-type="fig"}).

### Evaluation of publication bias

The RevMan funnel plot for the genotype model exhibited relative symmetry, whereas the allele model exhibited incomplete symmetry ([Fig. 4](#f4-etm-0-0-3734){ref-type="fig"}). Following Egger\'s linear regression analysis and Begg\'s rank correlation test, it was demonstrated that the studies on genotype had no statistically significant publication bias (bias factors, −0.156; P=0.658 of Egger\'s; P=0.584 of Begg\'s), whereas those on alleles did have some bias (bias factors, −16.716; P=0.002 of Egger\'s; P=0.009 of Begg\'s) ([Table III](#tIII-etm-0-0-3734){ref-type="table"} and [Fig. 5](#f5-etm-0-0-3734){ref-type="fig"}). N~fs0.05~ was equal to 750.604, which was large enough to warrant ignoring the publication bias.

Discussion
==========

The *CLU* gene is located on p21-p12 of human chromosome 8, with CLU as its encoded product, which has various physiological functions, including participating in lipid metabolism ([@b28-etm-0-0-3734]), oxidative stress reaction ([@b29-etm-0-0-3734]), and cell cycle regulation ([@b30-etm-0-0-3734]). *CLU* is highly expressed in cerebrospinal fluid and amyloid plaques in brain tissues, and is involved in the pathogenesis of AD ([@b4-etm-0-0-3734],[@b5-etm-0-0-3734],[@b31-etm-0-0-3734]). Yerbury *et al* ([@b32-etm-0-0-3734]) demonstrated that the deposition of CLU in senile plaques and neurofibrillary tangles of AD. Howlett *et al* ([@b33-etm-0-0-3734]) further reported a correlation between CLU and senile plaque Aβ40 in the brain cortex of patients with AD. Martin-Rehrmann *et al* ([@b34-etm-0-0-3734]) demonstrated the presence of dysfunctional neurons with phosphorylated tau protein surrounding the senile plaques in 71% of *CLU*-positive patients with AD. Furthermore, they also showed that the tau and phosphorylated tau protein were significantly increased in the rat hippocampus, following the injection of a CLU-rich solution ([@b34-etm-0-0-3734]). It was suggested that CLU may be involved in the formation of Aβ and dysfunctional neurons in the pathological state of AD ([@b5-etm-0-0-3734]). Wahrle *et al* ([@b35-etm-0-0-3734]) reported that CLU regulated the expression and metabolism of APOE in the brain. Indeed, the levels of cholesterol and APOE were decreased in the mouse following *CLU* gene knocked out. Aβ and clusterin combine together in normal cerebrospinal fluid, which suggested that CLU may be involved in the metabolism, transportation and clearance of Aβ in the brain ([@b30-etm-0-0-3734]). Bell *et al* ([@b36-etm-0-0-3734]) demonstrated that the clearance of Aβ42 through the blood brain barrier was increased by 83% when it was combined with CLU. Thambisetty *et al* ([@b37-etm-0-0-3734]) demonstrated the important role of CLU in the pathogenesis of AD. They showed that CLU was associated with atrophy of the entorhinal cortex and rapid clinical progression of AD ([@b37-etm-0-0-3734]). The higher the plasma concentration levels of CLU, the more significant the entorhinal cortex atrophy, and the more severe the cognitive impairment ([@b37-etm-0-0-3734]). It was also demonstrated that increased plasma concentration levels of CLU was predictive of greater Aβ burden in the medial temporal lobe ([@b31-etm-0-0-3734]). In view of the above results, it was hypothesized that gene mutations or specific environmental factors could induce changes in *CLU* gene expression or function, which have an important role in the pathogenesis of AD.

Since October 2009, association studies between the *CLU* gene polymorphism and LOAD susceptibility have rapidly progressed worldwide, and have been conducted in numerous populations, including Caucasian, Asian, African descent, and Hispanic populations ([@b6-etm-0-0-3734],[@b7-etm-0-0-3734],[@b9-etm-0-0-3734]--[@b26-etm-0-0-3734]). Notably, SNP rs11136000 in the *CLU* gene was demonstrated to be significantly associated with LOAD by two GWAS with large sample sizes and two stages, of which one was conducted by Lambert *et al* ([@b6-etm-0-0-3734]) (OR, 0.86; 95% CI, 0.81--0.90; P=7.5×10^−9^) and the other by Harold *et al* ([@b7-etm-0-0-3734]) (OR, 0.86; 95% CI, 0.82--0.90; P=8.5×10^−10^). The meta-analysis carried out by Jones *et al* ([@b38-etm-0-0-3734]) also supported the above conclusion (P=1.72 × 10^−15^). From then on, numerous other studies obtained concordant or non-concordant results ([@b9-etm-0-0-3734]--[@b26-etm-0-0-3734]). An issue is that many of the studies differ in their selection of ethnic genetic backgrounds and sample sizes, which leads to inconsistent or contrary conclusions regarding the association between gene polymorphism and diseases. The present study performed a meta-analysis to systematically review the published articles regarding the association between the *CLU* polymorphism rs11136000 and LOAD susceptibility, with increased sample size to improve and enhance test efficiency and ethnic subgroups to eliminate possible ethnic differences. This investigation aimed to provide objective results of evidence-based medicine for the association between *CLU* gene polymorphisms and AD susceptibility. The results of the present study demonstrated a positive association between *CLU* gene polymorphisms and LOAD susceptibility, as expected.

In the present study, 20 studies of interest were included in a meta-analysis, covering 33 independent study populations from various regions, ethnicities and stages, all meeting the predetermined inclusion criteria. The results demonstrated that there were some differences in the association between rs11136000 and LOAD among the various ethnicities. Meta-analysis supported the following conclusions: 1) TT+TC genotypes and the T allele of rs11136000 in Caucasian populations are associated with LOAD, as for the overall-effect test P\<0.01; 2) TT+TC genotypes and the T allele of rs11136000 in Asian populations is associated with LOAD, as for the overall-effect test both P\<0.05; 3) the T allele of rs11136000 in the population of African descent and the Hispanic population was not associated with LOAD, as for the single tests P\>0.05; and 4) the T allele of rs11136000 in the other/mixed ethnicity group was associated with LOAD, as for the overall-effect test P\<0.05. To summarize, the meta-analysis demonstrated that TT+TC genotypes and (or) the T allele of rs11136000 in Caucasian, Asian, and other/mixed ethnicity populations were associated with LOAD (P\<0.05), and the population carrying the T allele would likely suffer lower LOAD risk (OR\<1). The results therefore demonstrated that the T allele of rs11136000 had a protective effect on LOAD. The results also demonstrated the impact of racial differences on association studies of gene polymorphisms and disease.

In addition to ethnic differences, sample size also had an important effect on the study results. In the present meta-analysis, there was only one study population of African descent or Hispanic population included ([@b17-etm-0-0-3734]), with a relatively small sample size, which may not have provided accurate results. For instance, in the studies conducted in the Chinese Han population, Yu *et al* ([@b25-etm-0-0-3734]), Chen *et al* ([@b15-etm-0-0-3734]) and Ma *et al* ([@b20-etm-0-0-3734]) did not report any statistical significance in the T allele distribution of rs11136000 (P=0.21, 0.22, 0.42, respectively). However, when sample size was enlarged through meta-analysis and the three studies were included, a weak association was revealed (P=0.048 in the overall effect test). The majority of the studies and those with the largest sample size were conducted in the Caucasian population in the current meta-analysis, and therefore the results obtained for the Caucasian population are the most reliable. Further studies are required in other ethnic groups with larger sample sizes in order to improve the reliability of the study findings.

It is not only rs11136000 but also other polymorphisms of the *CLU* gene may contribute to LOAD susceptibility. For instance, the study carried out by Yu *et al* ([@b25-etm-0-0-3734]) in the Chinese Han population did not find an association between rs11136000 and LOAD, although the results indicated instead an association between rs9331888 and LOAD, with OR=1.39 (95% CI, 1.13--1.72) and P=0.002. Other studies also demonstrated the association between polymorphisms of rs9331888 ([@b6-etm-0-0-3734],[@b11-etm-0-0-3734],[@b25-etm-0-0-3734]), rs2279590 ([@b6-etm-0-0-3734],[@b15-etm-0-0-3734],[@b21-etm-0-0-3734],[@b23-etm-0-0-3734]), rs7982 ([@b7-etm-0-0-3734],[@b17-etm-0-0-3734]), rs7012010 ([@b7-etm-0-0-3734],[@b17-etm-0-0-3734]), rs9331908 ([@b12-etm-0-0-3734]), rs1532278 ([@b12-etm-0-0-3734],[@b39-etm-0-0-3734]), and rs9331949 ([@b40-etm-0-0-3734]) and LOAD, although these studies were few and inconsistent in their results. The rs11136000 polymorphism systematically reviewed in the present meta-analysis is likely one of the factors that influences LOAD susceptibility. The precise forms of the genetic variants require further investigation. The meta-analysis only involved rs11136000, the most well-established *CLU* gene polymorphism, but was not representative of the entire *CLU* gene. The results of the meta-analysis supported that the *CLU* gene polymorphism was associated with LOAD susceptibility in Caucasian and Asian populations, but there was no such definitive association in populations of African descent or Hispanic populations.

In conclusion, although the studies included in the meta-analysis of the present investigation were less than those conducted on the APOE gene, all were published in authorized journals after 2009, which indicated that the research on the *CLU* gene polymorphism was novel and promising. It is likely that the *CLU* polymorphism will be the subject of numerous studies on the genetic susceptibility to AD in the future. Further investigations are required in various ethnic population. The present meta-analysis will be regularly updated in order to draw more scientific and reliable conclusions regarding the association between the *CLU* gene polymorphism and susceptibility to LOAD.

There are clinical significances and wider implications of the findings in the present study. For example, there may be a use in monitoring disease progression in the elderly at risk. Furthermore, understanding the influence of the LOAD risk variants on cognitive decline may provide additional information with regard to their plausible mechanism of action.
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###### 

Characteristics of the studies included in the meta-analysis.

                                                               LOAD          Control                                                                                            
  ------------------------------ ----------------------- ----- ------------- --------- ---------- ----------- --------------- ----------- ------------------------------------- -----------------------
  Caucasian                                                                                                                                                                     
    Lambert *et al*, 2009        Stage 1 (France)        Pos   2,025 (66%)   C         68.3±9.0   73.7±8.9    5,328 (61%)     73.8±5.4    Illumina infinium system              ([@b6-etm-0-0-3734])
                                 Stage 2 (Italy)         Pos   1,520 (68%)   C         73.8±8.8   76.6±8.7    1,291 (55%)     72.3±8.9    Illumina infinium system              
                                 Stage 2 (Spain)         Neg   755 (57%)     C         72.5±9.4   75.3±9.3    833 (62%)       76.9±10.9   Illumina infinium system              
                                 Stage 2 (Belgium)       Pos   1,084 (66%)   C         74.4±8.6   78.6±8.1    509 (58%)       67.0±12.9   Illumina infinium system              
                                 Stage 2 (Finland)       Pos   619 (67%)     C         71.4±7.5   71.4±7.5    664 (60%)       69.2±6.0    Illumina infinium system              
    Harold *et al*, 2009         Stage 1 (USA)           Pos   1,159 (58%)   M         73.5       80.7        1,783 (56%)     68.1        Illumina infinium system              ([@b7-etm-0-0-3734])
                                 Stage 1 (UK, Ireland)   Pos   2,227 (65%)   M         72.9       79.7        5,241 (53%)     51.2        Illumina infinium system              
                                 Stage 1 (Germany)       Pos   555 (64%)     C         70.5       72.9          824 (51%)     56.5        Illumina infinium system              
    Giedraitis *et al*, 2009     Sweden (ULSAM)          Neg   86 (0%)       C         80.2       --          404 (0%)        81.8        Illumina GoldenGate assay             ([@b9-etm-0-0-3734])
    Golenkina *et al*, 2010      Russian                 Neg   534 (−)       C         --         --          702 (−)         --          --                                    ([@b10-etm-0-0-3734])
    Jun *et al*, 2010            USA (ADGC-C)            Pos   5,935 (−)     M         --         --          7,034 (−)       --          Illumina or affymetrix arrays         ([@b17-etm-0-0-3734])
    Seshadri *et al*, 2010       Spain (ACE)             Pos   1,140 (70%)   C         --         78.8±7.9    1,209 (53%)     49.9±9.2    Illumina or affymetrix arrays         ([@b24-etm-0-0-3734])
    Carrasquillo *et al*, 2010   USA                     Pos   1,829 (−)     M         --         --          2,576 (−)       --          TaqMan SNP genotyping assays          ([@b13-etm-0-0-3734])
    Schjeide *et al*, 2011       Germany                 Neg   214           C         --         --          211 (−)         --          OpenArray genotyping system           ([@b23-etm-0-0-3734])
                                 USA                     Pos   2,654         M         --         --          1,175 (−)       --          OpenArray genotyping system           
    Bettens *et al*, 2012        Stage 1 (Belgium)       Pos   1,057 (66%)   C         74.9±8.9   --          873 (57.4%)     65.1±14.9   PCR                                   ([@b12-etm-0-0-3734])
                                 Stage 2 (France)        Neg   1,465 (66%)   C         69.5±8.2   --          717 (62.3%)     74.0±8.0    PCR                                   
                                 Stage 2 (Canada)        Neg   323 (55%)     C         75.3±9.7   --          250 (60.0%)     73.0±10.2   PCR                                   
    Kamboh *et al*, 2012         USA                     Neg   1,348 (66%)   M         72.6±6.4   --          1,359 (61%)     74.7±6.5    TaqMan SNP genotyping assays          ([@b18-etm-0-0-3734])
    Carrasquillo *et al*, 2014   USA                     Pos   54 (76%)      N         --         --          2,523 (56.7%)   --          TaqMan SNP genotyping assays          ([@b14-etm-0-0-3734])
  Asian                                                                                                                                                                         
    Yu *et al*, 2010             China                   Neg   324 (56%)     C         --         76.8±5.5    388 (54%)       75.9±4.6    MALDI-TOF mass spectrometry           ([@b25-etm-0-0-3734])
    Gu *et al*, 2011             Indiana                 Neg   106 (56%)     C         --         76.7±7.0    98 (55.1%)      76.1±7.1    PCR                                   ([@b11-etm-0-0-3734])
    Ohara *et al*, 2012          Japan                   Pos   824 (77%)     C         --         83.2±6.5    2,933 (56.0%)   60.2±11.5   Invader assay                         ([@b22-etm-0-0-3734])
    Lin *et al*, 2012            Taiwan                  Pos   268 (−)       C         --         --          389 (−)         --          --                                    ([@b19-etm-0-0-3734])
    Chen *et al*, 2012           Hong Kong               Neg   462 (−)       C         --         --          350 (−)         --          Sequenom platform                     ([@b15-etm-0-0-3734])
    Ma *et al*, 2012             China                   Neg   127 (58%)     C         --         73.1±8.6    143 (55.2%)     73.8±6.3    PCR-RFLP                              ([@b20-etm-0-0-3734])
    Miyashita *et al*, 2013      Stage 1 (Japan)         Pos   1,008 (72%)   C         73.0±4.3   --          1,016 (57%)     77.0±5.9    Affymetrix GeneChip 6.0 microarrays   ([@b21-etm-0-0-3734])
                                 Stage 3 (Korean)        Pos   339 (72%)     C         --         73.7±9.5    1,129 (49%)     71.0±4.9    TaqMan assays                         
    Lu *et al*, 2014             Stage 2 (China)         Neg   499 (55%)     C         --         70.0±10.0   592 (59.3%)     68.9±9.4    PCR-RFLP                              ([@b26-etm-0-0-3734])
  African descent                                                                                                                                                               
    Jun *et al*, 2010            USA (ADGC-AA)           Neg   462 (−)       M         --         --          449 (−)         --          Illumina 660Quad                      ([@b17-etm-0-0-3734])
  Hispanics                                                                                                                                                                     
    Jun *et al*, 2010            USA (ADGC-H)            Neg   549 (−)       M         --         --          544 (−)         --          Illumina HumanHap 650Y chip           ([@b17-etm-0-0-3734])
  Other/Mixed                                                                                                                                                                   
    Jun *et al*, 2010            USA (ADGC-Wadi Ara)     Neg   124 (−)       M         --         --          142 (−)         --          Illumina 660Quad                      ([@b17-etm-0-0-3734])
    Ferrari *et al*, 2012        UK                      Pos   342 (59%)     C         76.8±8.6   --          277 (64.6%)     70.2±8.6    TaqMan SNP genotyping assays          ([@b16-etm-0-0-3734])

Pos, positive: statistically significant; Neg, negative: non statistically significant; Alzheimer\'s disease diagnostic criteria: C, clinical criteria; N, neuropathological criteria; M, mixture of clinical and neuropathological criteria; -, no data obtained; PCR, polymerase chain reaction; SNP, single nucleotide polymorphism; RFLP, restriction fragment length polymorphism; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; ADGC-C, the Alzheimer\'s Disease Genetics Consortium-Caucasian; ADGC-AA, the ADGC-African American; ADGC-H, ADGC-Hispanics; ADGC-Wadi Ara, ADGC-Wadi Arab.

###### 

Distribution of *CLU* rs11136000 genotypes and alleles among LOAD cases and controls in the included studies.

                                                     Genotype distribution (%)   Allele distribution (%)                                                                                                        
  -------------------------------------------------- --------------------------- ------------------------- -------- -------- -------- -------- -------- -------- -------- -------- -------- ------ ------------ ---------
  Lambert *et al*, 2009 ([@b6-etm-0-0-3734])         Stage 1 (France)            270                       900      869      860      2,561    1,957    1,440    2,638    4,281    6,475    0.83   0.77, 0.89   −5.0122
                                                                                 (13.2)                    (44.1)   (42.6)   (16.0)   (47.6)   (36.4)   (35.3)   (64.7)   (39.8)   (60.2)                       
                                                     Stage 2 (Italy)             197                       682      601      211      570      482      1,076    1,884    992      1,534    0.88   0.79, 0.99   −2.2241
                                                                                 (13.3)                    (46.1)   (40.6)   (16.7)   (45.1)   (38.2)   (36.4)   (63.6)   (39.3)   (60.7)                       
                                                     Stage 2 (Spain)             99                        344      305      112      389      309      542      954      613      1,007    0.93   0.81, 1.08   −0.9293
                                                                                 (13.2)                    (46.0)   (40.8)   (13.8)   (48.0)   (38.1)   (36.2)   (63.8)   (37.8)   (62.2)                       
                                                     Stage 2 (Belgium)           155                       472      408      79       241      171      782      1,288    399      583      0.89   0.76, 1.04   −1.5117
                                                                                 (15.0)                    (45.6)   (39.4)   (16.1)   (49.1)   (34.8)   (37.8)   (62.2)   (40.6)   (59.4)                       
                                                     Stage 2 (Finland)           86                        286      224      109      323      218      458      734      541      759      0.88   0.75, 1.03   −1.6241
                                                                                 (14.4)                    (48.0)   (37.6)   (16.8)   (49.7)   (33.5)   (38.4)   (61.6)   (41.6)   (58.4)                       
  Harold *et al*, 2009 ([@b7-etm-0-0-3734])          Stage 1 (USA)               163                       509      481      328      1,085    774      835      1,471    1,741    2,633    0.86   0.77, 0.95   −2.8678
                                                                                 (14.1)                    (44.1)   (41.7)   (15.0)   (49.6)   (35.4)   (36.2)   (63.8)   (39.8)   (60.2)                       
                                                     Stage 1                     295                       1038     887      787      2323     1,723    1,628    2,812    3,897    5769     0.86   0.80, 0.92   −4.1228
                                                     (UK, Ireland)               (13.3)                    (46.8)   (40.0)   (16.3)   (48.1)   (35.7)   (36.7)   (63.3)   (40.3)   (59.7)                       
                                                     Stage 1 (Germany)           66                        240      233      144      368      294      372      706      656      956      0.76   0.65, 0.89   −3.2328
                                                                                 (12.2)                    (44.5)   (43.2)   (17.5)   (46.8)   (35.7)   (34.5)   (65.5)   (40.7)   (59.3)                       
  Giedraitis *et al*, 2009 ([@b9-etm-0-0-3734])      Sweden                      15                        31       33       59       166      140      61       97       284      446      0.99   0.69, 1.41   −0.0693
                                                                                 (19.0)                    (39.2)   (41.8)   (16.2)   (45.5)   (38.4)   (38.6)   (61.4)   (38.1)   (61.1)                       
  Golenkina *et al*, 2010 ([@b10-etm-0-0-3734])      Russian                     58                        262      214      99       341      262      378      690      539      865      0.88   0.75, 1.04   −1.5277
                                                                                 (10.9)                    (49.0)   (40.1)   (14.1)   (48.6)   (37.3)   (35.4)   (64.6)   (38.4)   (61.6)                       
  Jun *et al*, 2010 ([@b17-etm-0-0-3734])            USA (ADGC-C)                --                        --       --       --       --       --       --       --       --       --       0.91   0.85, 0.96   −3.7532
                                                     USA (ADGC-AA)               --                        --       --       --       --       --       --       --       --       --       1.06   0.89, 1.28   0.6172
                                                     USA (ADGC-H)                --                        --       --       --       --       --       --       --       --       --       1.10   0.91, 1.32   1.1137
                                                     USA                         --                        --       --       --       --       --       --       --       --       --       0.96   0.69, 1.32   −0.2141
                                                     (ADGC-Wadi Ara)                                                                                                                                            
  Seshadri *et al*, 2010 ([@b24-etm-0-0-3734])       Spain (ACE)                 148                       525      467      184      575      450      821      1459     943      1475     0.88   0.78, 0.99   −2.1150
                                                                                 (13.0)                    (46.1)   (41.0)   (15.2)   (47.6)   (37.2)   (36.0)   (64.0)   (39.0)   (61.0)                       
  Carrasquillo *et al*, 2010 ([@b13-etm-0-0-3734])   USA                         249                       848      722      431      1,241    893      1,346    2,292    2,103    3,027    0.85   0.77, 0.92   −3.7725
                                                                                 (13.7)                    (46.6)   (39.7)   (16.8)   (48.4)   (34.8)   (37.0)   (63.0)   (41.0)   (59.0)                       
  Yu *et al*, 2010 ([@b25-etm-0-0-3734])             China                       2                         104      218      12       126      250      108      540      150      626      0.83   0.64, 1.10   −1.2983
                                                                                 (0.6)                     (32.1)   (67.3)   (3.1)    (32.5)   (64.4)   (16.7)   (83.3)   (19.3)   (80.7)                       
  Schjeide *et al*, 2011 ([@b23-etm-0-0-3734])       Germany                     --                        --       --       --       --       --       --       --       --       --       0.99   0.83, 1.27   −0.0905
                                                     USA                         --                        --       --       --       --       --       --       --       --       --       0.84   0.73, 0.96   −3.4529
  Gu *et al*, 2011 ([@b11-etm-0-0-3734])             Indiana                     4                         72       30       6        67       25       80       132      79       117      0.90   0.60, 1.34   −0.5318
                                                                                 (3.8)                     (67.9)   (28.3)   (6.1)    (68.4)   (25.5)   (37.7)   (62.3)   (40.3)   (59.7)                       
  Ohara *et al*, 2012 ([@b22-etm-0-0-3734])          Japan                       60                        295      469      242      1,156    1,535    415      1,233    1,640    4,226    0.87   0.77, 0.98   −2.2324
                                                                                 (7.3)                     (35.8)   (56.9)   (8.3)    (39.4)   (52.3)   (25.2)   (74.8)   (28.0)   (72.0)                       
  Lin *et al*, 2012 ([@b19-etm-0-0-3734])            Taiwan                      3                         89       176      29       118      242      95       441      176      602      0.74   0.56, 0.97   −2.1521
                                                                                 (1.1)                     (33.2)   (65.7)   (7.5)    (30.3)   (62.2)   (17.7)   (82.3)   (22.6)   (77.4)                       
  Chen *et al*, 2012 ([@b15-etm-0-0-3734])           Hong Kong                   15                        162      274      24       114      200      192      710      162      514      0.86   0.68, 1.09   −1.2616
                                                                                 (3.3)                     (35.9)   (60.8)   (7.1)    (33.7)   (59.2)   (21.3)   (78.7)   (24.0)   (76.0)                       
  Bettens *et al*, 2012 ([@b12-etm-0-0-3734])        Stage 1 (Belgium)           --                        --       --       --       --       --       676      1,232    630      990      0.79   0.68, 0.93   −2.1199
                                                                                                                                                        (35.4)   (64.6)   (38.9)   (61.1)                       
                                                     Stage 2 (France)            --                        --       --       --       --       --       875      1,707    452      764      0.93   0.79, 1.10   −1.9789
                                                                                                                                                        (33.9)   (66.1)   (37.2)   (62.8)                       
                                                     Stage 2 (Canada)            --                        --       --       --       --       --       236      372      179      299      1.00   0.77, 1.31   0.4606
                                                                                                                                                        (38.8)   (61.2)   (37.4)   (62.6)                       
  Kamboh *et al*, 2012 ([@b18-etm-0-0-3734])         USA                         179                       623      542      195      636      519      981      1707     1,026    1,674    0.94   0.84, 1.05   −1.1420
                                                                                 (13.3)                    (46.4)   (40.3)   (14.4)   (47.1)   (38.4)   (36.5)   (63.5)   (38.0)   (62.0)                       
  Ferrari *et al*, 2012 ([@b16-etm-0-0-3734])        UK                          --                        --       --       --       --       --       254      430      242      312      0.76   0.60, 0.96   −2.3357
                                                                                                                                                        (37.1)   (62.9)   (43.7)   (56.3)                       
  Ma *et al*, 2012 ([@b20-etm-0-0-3734])             China                       7                         39       81       5        58       80       53       201      68       218      0.85   0.56, 1.27   −0.8090
                                                                                 (5.5)                     (30.7)   (63.8)   (3.5)    (40.6)   (55.9)   (20.9)   (79.1)   (23.8)   (76.2)                       
  Miyashita *et al*, 2013 ([@b21-etm-0-0-3734])      Stage 1 (Japan)             --                        --       --       --       --       --       --       --       --       --       0.87   0.78, 0.97   −2.0100
                                                     Stage 3 (Korean)            --                        --       --       --       --       --       --       --       --       --       0.79   0.63, 0.98   −2.3006
  Carrasquillo *et al*, 2014 ([@b14-etm-0-0-3734])   USA                         4                         25       25       416      1,165    843      33       75       1,997    2,851    0.60   0.39, 0.92   −2.2044
                                                                                 (7.4)                     (46.3)   (46.3)   (17.2)   (48.0)   (34.8)   (30.6)   (69.4)   (41.2)   (58.8)                       
  Lu *et al*, 2014 ([@b26-etm-0-0-3734])             Stage 2 (China)             18                        156      319      23       161      399      192      794      207      959      1.12   0.90, 1.39   1.0224
                                                                                 (3.7)                     (31.6)   (64.7)   (4.0)    (27.6)   (68.4)   (19.5)   (80.5)   (17.8)   (82.2)                       

LOAD, late-onset Alzheimer\'s disease; CI, confidence interval; OR, odds ratio; ADGC-C, the Alzheimer\'s Disease Genetics Consortium-Caucasian; ADGC-AA, ADGC-African American; ADGC-H, ADGC-Hispanics; ADGC-Wadi Ara, ADGC-Wadi Arab.

###### 

Results of Egger\'s linear regression analysis and Begg\'s rank correlation test for publication bias.

             Egger\'s test   Begg\'s test                                                                                  
  ---------- --------------- -------------- ----------- ------- ------- ----------------------- ------ ------- ---- ------ -------
  Genotype   Slope           0.2160835      0.0287501   7.52    0.000   0.1534424, 0.2787246    −11    18.27   14   0.55   0.584
             bias            −0.1556121     0.3430764   −0.45   0.658   −0.9031114, 0.5918871                              
  Allele     Slope           −0.0658025     0.3326355   −0.20   0.844   −0.744217, 0.0612612    −170   64.54   33   2.62   0.009
             bias            −16.71626      5.075586    −3.29   0.002   −27.06799, −6.364535                               

Coefficient was the intercept of regression analysis. P\>ltl = 0.658, 0.002; Pr\>lzl = 0.584, 0.009 (where both stand for no bias). SE, standard error; SD, standard deviation; Std-Eff, standard effect.
